Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | TEC | P42680 | 1/20 | 0.49 |
| ▸ | TXK | P42681 | 1/20 | 0.49 |
| ▸ | BLK | P51451 | 1/20 | 0.49 |
| ▸ | BMX | P51813 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.49 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19877414 | 1.00 | BTK (0.62) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL19877417 | 1.00 | BTK (0.62) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL19877993 | 1.00 | BTK (0.62) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL19877807 | 0.97 | BTK (0.63) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL19877626 | 0.97 | BTK (0.63) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL19877624 | 0.97 | BTK (0.63) | BTKEGFRERBB2ADORA3PTGS2 | |
| SCHEMBL19877777 | 0.91 | BTK (0.55) | BTK | |
| SCHEMBL19877592 | 0.90 | BTK (0.56) | BTK | |
| SCHEMBL19877763 | 0.90 | BTK (0.50) | BTK | |
| SCHEMBL30167350 | 0.90 | BTK (0.50) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006035-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Neupharma, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |